

China Sunsine Chemical Holdings Ltd

Potential growth from pipeline projects

SINGAPORE | MATERIALS | 2Q19 RESULTS

- 2Q19 revenue and net profit met our expectation.
- Second record-high profit margin with a decent growth of volume (GPM and NPM: 34.7% and 21.4%). ASP yet to bottom.
- Capacity expansion projects in the pipeline: 20,000 tonnes Accelerator TBBS and 60,000 tonnes IS.
- We maintain FY19e and FY20e EPS at 21.0 SG cents and 22.0 SG cents respectively.
 Based on the same required rate of return of 10%, we maintain our BUY recommendation with an unchanged target price of \$\$1.43.

Results at a glance

results at a gial			
(RMB mn)	2Q19	2Q18	YoY (%) Comments
Revenue	727	881	(17) Decrease in overall ASP, offsetting the
			inrease in sales volumes due partially to
			the ramp-up of capacity
Gross profit	252	324	(22) Lower ASP
PBT	188	215	(13) Reversal of management remuneration
PAT	156	240	(35) Tax credit of RMB24.9mn in 2Q18

Source: Company, PSR

The Positive

+ Second record-high profit margin with a decent growth of volume. 2Q19 GPM and NPM arrived at 34.7% and 21.4%, compared to the record high of 36.7% and 27.2%* in 2Q18 respectively (1Q19 GPM and NPM: 34.3% and 16.0%). Gross profit/tonne dropped 32.3% YOY or 4.5% QoQ to RMB5,886/tonne during the period, which was owing to the narrow spread between ASP and raw material (main: aniline) prices. The spread fell by 19.1% YOY and 10.2% QoQ to RMB11,400/tonne in 2Q19. The respective implied capacity utilisation rate of Accelerators, Insoluble Sulphur (IS), and Anti-oxidant arrived at 97.2%, 101.0%, and 104.0% in 2Q19. Therefore, the production lines were running full during the period.

Sales volume

(mn tonnes)	2Q19	2Q18	YoY (%)	1Q18	QoQ (%)
Accelerators	23,583	21,563	9.4	19,907	18.5
Insoluble Sulphur	7,577	6,672	13.6	6,212	22.0
Anti-oxidant	11,701	8,986	30.2	10,353	13.0

Average selling price

(RMB/tonne)	2Q19	2Q18	YoY (%)	1Q18	QoQ (%)
Accelerators	20,693	29,486	-29.8	29,387	-29.6
Insoluble Sulphur	9,252	11,706	-21.0	11,719	-21.1
Anti-oxidant	13,247	17,182	-22.9	17,995	-26.4

Source: Company, PSR

The Negative

- **ASP is yet bottomed.** The YoY plunge of performance in 2Q19 was due mainly to the phenomenally high ASP in 2Q18. The downtrend beginning in 3Q18 continued. However, the aniline price slightly recovered by 6% QoQ to RMB5,200/tonne during the period.



8 August 2019

BUY (Maintained)

TOTAL RETURN	36.3%
TARGET PRICE	SGD 1.430
FORECAST DIV	SGD 0.042
CLOSING PRICE	SGD 1.080

COMPANY DATA

Bloomberg Code:	CSSC SP
O/S SHARES (MN) :	489
MARKET CAP (USD mn / SGD mn):	382/528
52 - WK HI/LO (SGD) :	1.5/0.91
3M Average Daily T/O (mn):	0.36

MAJOR SHAREHOLDERS (%)

SUCCESS MORE GROUP	60.1%
DIMENSIONAL FUND ADVISSORS LP	1.4%
KOH CHOON KONG	0.9%

PRICE PERFORMANCE (%)

	1MTH	ЗМТН	1YR
COMPANY	(5.3)	(4.1)	(22.0)
STI RETURN	(5.2)	(2.7)	0.6

PRICE VS. STI



Source: Bloomberg, PSR

KEY FINANCIALS

Y/E Dec, RMB mn	FY17	FY18	FY19e	FY20e
Revenue	2,738	3,283	3,058	3,184
Gross profit	788	1,126	978	1,019
PAT	341	641	516	540
P/E (x)	9.8	3.3	5.2	5.0
P/B (x)	1.9	0.9	1.0	0.9
ROE	20%	28%	19%	17%
ROA	16%	23%	17%	15%

Source: PSR

VALUATION METHOD

FCFE (Cost of Equity: 10.0%; Terminal g: 0.5%)

Chen Guangzhi Research Analyst chengz@phillip.com.sg (+65 6212 1859)


Page | 1 | PHILLIP SECURITIES RESEARCH (SINGAPORE)

MCI (P) 062/10/2018 Ref. No.: SG2019_0140

^{*} Excluding the one-off tax credit of RMB48mn, the adjusted NPM was 21.8% in 2Q18.



Figure 1: Price spread (accelerator/antioxidant and aniline)



Source: CEIC, PSR

Outlook

CSSC is experiencing a cyclical downturn in ASP after the peak in 2Q18. Nonetheless, the timely and visionary capacity expansion initiated before the price correction mitigates the price headwinds. The company manages to deliver a healthy performance owing to the established buffers, including the quality products, solid and long-term relationship with clients, and leading market position. Therefore, we believe the company will deliver more than 30% GPM and 16% NPM in 2019. The future growth still stems from the ramp-up of capacity, including 20,000 tonnes of Accelerator TBBS (scheduled in 2019/2020) and 60,000 tonnes of IS (under planning), and both can be internally funded. According to management, the rationale that choosing IS for the next production expansion is that 1) China still imports IS and 2) IS has the highest GPM (around 40%) among the category. In the next couple of years, we foresee that CSSC's performance will level up once the new production lines commence and ASP bottoms out.

Maintain BUY with an unchanged TP of S\$1.43

We maintain FY19e and FY20e EPS at 21 SG cents and 22 SG cents respectively. Based on the same required rate of return of 10%, we maintain our BUY recommendation with an unchanged target price of \$\$1.43.

Y/E, RMB mn	FY19e	FY20e	FY21e
Net income	516	540	516
Net capex	110	120	110
Chang in net WC	2	130	73
Change in borrowing	-	-	-
FCFE	404	290	333
Beta	1.45		
Required rate of return	10.0%		
Growth	0.5%		
FX (SGD/RMB)	4.96		
TP (SGD)	1.43		

Source: PSR




Financials

Income Statement						Balance Sheet					
Y/E Dec, RMB mn	FY16	FY17	FY18	FY19e	FY20e	Y/E Dec, RMB mn	FY16	FY17	FY18	FY19e	
Revenue	2,037	2,738	3,283	3,058	3,184	ASSETS					
COGS	(1,497)	(1,950)	(2,157)	(2,079)	(2,165)	PP&E	549	662	691	688	
Gross profit	540	788	1,126	978	1,019	Others	43	41	40	39	
EBITDA	410	567	809	728	762	Total non-current assets	592	703	731	727	
Depreciation & Amortisation	96	90	98	106	111	Cash	276	500	1,039	1,267	
EBIT	314	477	712	622	650	Inventories	145	212	217	386	
Net Finance (Expense)/Inc	(4)	-	-	-	-	Trade receivables	548	638	691	664	
PBT	310	477	712	622	650	Others	82	75	70	66	
Taxation	(88)	(136)	(70)	(106)	(111)	Total current assets	1,051	1,425	2,016	2,383	:
PAT	222	341	641	516	540	Total Assets	1,642	2,128	2,747	3,110	:
Per share data						LIABILITIES					
//E Dec	FY16	FY17	FY18	FY19e	FY20e	Trade payables	52	71	63	71	
EPS (RMB cents)	47.7	69.4	130.5	105.0	109.8	Borrowings	-	-	-	-	
EPS (SG cents)	10.0	11.0	32.9	20.6	21.5	Others	229	314	359	353	
OPS (SG cents)	1.5	3.0	5.5	4.2	4.4	Total current liabilities	281	385	422	424	
BVPS (RMB)	2.9	3.5	4.7	5.5	6.3	Borrowings	-	-	-	-	
BVPS (SGD)	0.6	0.6	1.2	1.1	1.2	Total non-current liabilities	_	_	_	_	
3413 (302)	0.0	0.0	1.2	1.1	1.2	Total Liabilities	281	385	422	424	
Cash Flow	W14.6		T)// 0	T)/40	T1/00	Total Equity	1,362	1,742	2,326	2,686	3
//E Dec, RMB mn	FY16	FY17	FY18	FY19e	FY20e						
CFO	240	4	740	600	c=0						
PBT	310	477	712	622	650	Valuation Ratios	FV1C	FV17	FV10	FV10-	F
Adjustments	103	92	76	102	107	Y/E Dec	FY16	FY17	FY18	FY19e	- 1
VC changes	(124)	(83)	(2)	(130)	(340)	P/E (x)	10.8	9.8	3.3	5.2	
Cash generated from ops	412	569	787	724	757	P/B (x)	1.8	1.9	0.9	1.0	
Others	(85)	(100)	(84)	(106)	(111)	EV/EBITDA	5.9	3.9	2.1	2.0	
Cashflow from ops	327	469	703	618	646	Growth & Margins (%) Growth					
CFI						Revenue	10%	46%	43%	-13%	
CAPEX, net	(82.0)	(208.9)	(129.5)	(110.0)	(120.0)	Gross profit	10%	46%	43%	-13%	
Others	2.4	3.7	4.2	4.4	4.6	EBIT	5%	52%	49%	-13%	
Cashflow from investments	(80)	(205)	(125)	(106)	(115)	PAT	14%	54%	88%	-19%	
	, ,				, ,	Margins					
CFF						GP margin	27%	29%	34%	32%	
oans, net of repayments	(148)	-	-	-	-	EBIT margin	15%	17%	22%	20%	
Dividends	(33)	(47)	(59)	(136)	(106)	PAT margin	11%	12%	20%	17%	
Others	(8)	96	6	(15)	-	Key Ratios					
Cashflow from financing	(189)	50	(52)	(150)	(106)	ROE	16%	20%	28%	19%	
Net change in cash	59	314	525	362	425	ROA	13%	16%	23%	17%	
Effects of exchange rate	-	(9)	16	-	-	Net Debt or (Net Cash)	(276)	(500)	(1,039)	(1,267)	(
Ending cash	274	496	1,035	1,267	1,352	Gearing		Net cash		Net cash	Ne

Source: Company, PSR





PSR Rating System	m	
Total Returns	Recommendation	Rating
> +20%	Buy	1
+5% to +20%	Accumulate	2
-5% to +5%	Neutral	3
-5% to -20%	Reduce	4
< -20%	Sell	5

Remarks

We do not base our recommendations entirely on the above quantitative return bands. We consider qualitative factors like (but not limited to) a stock's risk reward profile, market sentiment, recent rate of share price appreciation, presence or absence of stock price catalysts, and speculative undertones surrounding the stock, before making our final recommendation



Contact Information (Singapore Research Team)

Head of Research

Paul Chew - paulchewkl@phillip.com.sg

Research Admin

Siti Nursyazwina - syazwina@phillip.com.sg

Banking & Finance | Healthcare

Tin Min Ying - tinmy@phillip.com.sg

Oil & Gas | Energy Chen Guangzhi - chengz@phillip.com.sg Telco | Technology Alvin Chia - alvinchiawy@phillip.com.sg

Property | REITs | Transport

Natalie Ong - natalieongpf@phillip.com.sg

US Equity

SINGAPORE

Raffles City Tower

250, North Bridge Road #06-00

Singapore 179101

Tel +65 6533 6001

Fax +65 6535 6631

Website: www.poems.com.sg

JAPAN

Phillip Securities Japan, Ltd.

4-2 Nihonbashi Kabuto-cho Chuo-ku,

Tokyo 103-0026

Tel +81-3 3666 2101

Fax +81-3 3666 6090

Website: www.phillip.co.jp

Phillip Securities Pte Ltd

China/HK Equity Zheng Jieyuan – zhengjy@phillip.com.sg

Edmund Xue - edmundxuejj@phillip.com.sg

Technical Analyst

Chua Wei Ren - chuawr@phillip.com.sg

Contact Information (Regional Member Companies) MALAYSIA

Phillip Capital Management Sdn Bhd

B-3-6 Block B Level 3 Megan Avenue II, No. 12, Jalan Yap Kwan Seng, 50450 Kuala Lumpur

> Tel +603 2162 8841 Fax +603 2166 5099

Website: www.poems.com.my

INDONESIA

PT Phillip Securities Indonesia

ANZ Tower Level 23B, JI Jend Sudirman Kav 33A Jakarta 10220 - Indonesia

Tel +62-21 5790 0800 Fax +62-21 5790 0809

Website: www.phillip.co.id

THAILAND

Phillip Securities (Thailand) Public Co. Ltd

15th Floor, Vorawat Building, 849 Silom Road, Silom, Bangrak, Bangkok 10500 Thailand Tel +66-2 6351700 / 22680999 Fax +66-2 22680921

Website www.phillip.co.th

FRANCE

King & Shaxson Capital Limited

3rd Floor, 35 Rue de la Bienfaisance 75008 Paris France Tel +33-1 45633100 Fax +33-1 45636017

Website: www.kingandshaxson.com

UNITED STATES Phillip Capital Inc

141 W Jackson Blvd Ste 3050 The Chicago Board of Trade Building Chicago, IL 60604 USA

Tel +1-312 356 9000 Fax +1-312 356 9005

Website: www.phillipusa.com

AUSTRALIA

Phillip Capital Limited Level 10, 330 Collins Street

Melbourne, Victoria 3000, Australia Tel +61-03 8633 9803

Fax +61-03 8633 9899

TURKEY

PhillipCapital Menkul Degerler

Dr. Cemil Bengü Cad. Hak Is Merkezi

No. 2 Kat. 6A Caglayan

34403 Istanbul, Turkey

Tel: 0212 296 84 84

Fax: 0212 233 69 29

Website: www.phillipcapital.com.tr

Website: www.phillipcapital.com.au

INDIA

PhillipCapital (India) Private Limited

No.1, 18th Floor, Urmi Estate 95, Ganpatrao Kadam Marg Lower Parel West, Mumbai 400-013 Maharashtra, India

Tel: +91-22-2300 2999 / Fax: +91-22-2300 2969

Website: www.phillipcapital.in

CAMBODIA

Phillip Bank Plc

Ground Floor of B-Office Centre,#61-64, Norodom Blvd Corner Street 306, Sangkat Boeung Keng Kang 1, Khan Chamkamorn, Phnom Penh, Cambodia

Tel: 855 (0) 7796 6151/855 (0) 1620 0769 Website: www.phillipbank.com.kh

HONG KONG

Phillip Securities (HK) Ltd

11/F United Centre 95 Queensway Hong Kong

Tel +852 2277 6600 Fax +852 2868 5307

Websites: www.phillip.com.hk

CHINA

Phillip Financial Advisory (Shanghai) Co Ltd

No 550 Yan An East Road, Ocean Tower Unit 2318, Postal code 200001 Tel +86-21 5169 9200 Fax +86-21 6351 2940

Website: www.phillip.com.cn

UNITED KINGDOM

King & Shaxson Capital Limited

6th Floor, Candlewick House, 120 Cannon Street, London, EC4N 6AS Tel +44-20 7426 5950

Fax +44-20 7626 1757 Website: www.kingandshaxson.com

SRI LANKA

Asha Phillip Securities Limited

No. 60, 5th Lane, Colombo 3, Sri Lanka Tel: (94) 11 2429 100

Fax: (94) 11 2429 199 Website: www.ashaphillip.net

DUBAI **Phillip Futures DMCC**

Member of the Dubai Gold and Commodities Exchange (DGCX) Unit No 601, Plot No 58, White Crown Bldg, Sheikh Zayed Road, P.O.Box 212291

Dubai-UAF Tel: +971-4-3325052 / Fax: + 971-4-3328895



Important Information

This report is prepared and/or distributed by Phillip Securities Research Pte Ltd ("Phillip Securities Research"), which is a holder of a financial adviser's license under the Financial Advisers Act, Chapter 110 in Singapore.

By receiving or reading this report, you agree to be bound by the terms and limitations set out below. Any failure to comply with these terms and limitations may constitute a violation of law. This report has been provided to you for personal use only and shall not be reproduced, distributed or published by you in whole or in part, for any purpose. If you have received this report by mistake, please delete or destroy it, and notify the sender immediately.

The information and any analysis, forecasts, projections, expectations and opinions (collectively, the "Research") contained in this report has been obtained from public sources which Phillip Securities Research believes to be reliable. However, Phillip Securities Research does not make any representation or warranty, express or implied that such information or Research is accurate, complete or appropriate or should be relied upon as such. Any such information or Research contained in this report is subject to change, and Phillip Securities Research shall not have any responsibility to maintain or update the information or Research made available or to supply any corrections, updates or releases in connection therewith.

Any opinions, forecasts, assumptions, estimates, valuations and prices contained in this report are as of the date indicated and are subject to change at any time without prior notice. Past performance of any product referred to in this report is not indicative of future results.

This report does not constitute, and should not be used as a substitute for, tax, legal or investment advice. This report should not be relied upon exclusively or as authoritative, without further being subject to the recipient's own independent verification and exercise of judgment. The fact that this report has been made available constitutes neither a recommendation to enter into a particular transaction, nor a representation that any product described in this report is suitable or appropriate for the recipient. Recipients should be aware that many of the products, which may be described in this report involve significant risks and may not be suitable for all investors, and that any decision to enter into transactions involving such products should not be made, unless all such risks are understood and an independent determination has been made that such transactions would be appropriate. Any discussion of the risks contained herein with respect to any product should not be considered to be a disclosure of all risks or a complete discussion of such risks.

Nothing in this report shall be construed to be an offer or solicitation for the purchase or sale of any product. Any decision to purchase any product mentioned in this report should take into account existing public information, including any registered prospectus in respect of such product.

Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may provide an array of financial services to a large number of corporations in Singapore and worldwide, including but not limited to commercial / investment banking activities (including sponsorship, financial advisory or underwriting activities), brokerage or securities trading activities. Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may have participated in or invested in transactions with the issuer(s) of the securities mentioned in this report, and may have performed services for or solicited business from such issuers. Additionally, Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may have provided advice or investment services to such companies and investments or related investments, as may be mentioned in this report.

Phillip Securities Research or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report may, from time to time maintain a long or short position in securities referred to herein, or in related futures or options, purchase or sell, make a market in, or engage in any other transaction involving such securities, and earn brokerage or other compensation in respect of the foregoing.

Investments will be denominated in various currencies including US dollars and Euro and thus will be subject to any fluctuation in exchange rates between US dollars and Euro or foreign currencies and the currency of your own jurisdiction. Such fluctuations may have an adverse effect on the value, price or income return of the investment.

To the extent permitted by law, Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may at any time engage in any of the above activities as set out above or otherwise hold an interest, whether material or not, in respect of companies and investments or related investments, which may be mentioned in this report. Accordingly, information may be available to Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, which is not reflected in this report, and Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may, to the extent permitted by law, have acted upon or used the information prior to or immediately following its publication. Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited its officers, directors, employees or persons involved in the issuance of this report, may have issued other material that is inconsistent with, or reach different conclusions from, the contents of this report.

The information, tools and material presented herein are not directed, intended for distribution to or use by, any person or entity in any jurisdiction or country where such distribution, publication, availability or use would be contrary to the applicable law or regulation or which would subject Phillip Securities Research to any registration or licensing or other requirement, or penalty for contravention of such requirements within such jurisdiction.

This report is intended for general circulation only and does not take into account the specific investment objectives, financial situation or particular needs of any particular person. The products mentioned in this report may not be suitable for all investors and a person receiving or reading this report should seek advice from a professional and financial adviser regarding the legal, business, financial, tax and other aspects including the suitability of such products, taking into account the specific investment objectives, financial situation or particular needs of that person, before making a commitment to invest in any of such products.

This report is not intended for distribution, publication to or use by any person in any jurisdiction outside of Singapore or any other jurisdiction as Phillip Securities Research may determine in its absolute discretion.

IMPORTANT DISCLOSURES FOR INCLUDED RESEARCH ANALYSES OR REPORTS OF FOREIGN RESEARCH HOUSES

Where the report contains research analyses or reports from a foreign research house, please note:

- (i) recipients of the analyses or reports are to contact Phillip Securities Research (and not the relevant foreign research house) in Singapore at 250 North Bridge Road, #06-00 Raffles City Tower, Singapore 179101, telephone number +65 6533 6001, in respect of any matters arising from, or in connection with, the analyses or reports; and
 - (ii) to the extent that the analyses or reports are delivered to and intended to be received by any person in Singapore who is not an accredited investor, expert investor or institutional investor, Phillip Securities Research accepts legal responsibility for the contents of the analyses or reports.